Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Enalapril Articles

SYNERGY WITH ANTIHYPERTENSIVES

12 October 1992

SAVE STUDY CONFIRMS ACE INHIBITOR BENEFITS

7 September 1992

PLENDIL LAUNCHED IN GERMANY

7 September 1992

FALL IN PROFITS AT BANYU

22 June 1992

ZANTAC TOPS MAIL ORDER SALES IN USA

8 June 1992

ASTRA'S PLENDIL HEADING FOR CHF INDICATION

25 May 1992

STRATEGIES TO ACHIEVE CRITICAL MASS

20 April 1992

TEN YEARS OF ACE INHIBITION

23 March 1992

MS&D GREECE SALES RISE 19%

3 February 1992

GOOD 1991 RESULTS FOR MERCK AND FOREST LABS

3 February 1992

BANYU PINS HOPESON LIPOVAS

20 January 1992

Showing 201-211 of 211 articles

Go to beginningPrevious
  • 1
  • 2
  • 3
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS